Clinical-Stage Radiopharma · Brisbane ↔ Cambridge
AdvanCell
"Changing the course of cancer treatment."
PHOTO: The AdvanCell mark, photographed where most breakthroughs actually live - on a website, not a billboard.
In a 40,000-square-foot facility on the edge of Brisbane, a shipment arrives that almost no one else on Earth could receive. It is Thorium-228, a radioactive parent isotope. Over the coming weeks, it will decay into something rarer still: Lead-212. That lead is the whole point. It is the warhead AdvanCell has spent six years learning to make, handle, and aim.
AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company. That phrase does a lot of quiet work. "Radiopharmaceutical" means it builds medicines that carry radiation directly to tumors. "Targeted alpha therapy" means the radiation is delivered by alpha particles, which travel only a few cell-widths and hit like a freight train. "Vertically integrated" means the part everyone else struggles with - actually producing the isotope - happens in-house.
The unglamorous truth of nuclear medicine: the chemistry is elegant, the supply chain is a nightmare, and whoever fixes the second one wins.
Targeted alpha therapy is not a new dream. Oncologists have wanted it for decades. Alpha particles deposit enormous energy over a microscopic range - perfect for shredding a cancer cell while the cell next door barely notices. On paper, it is the closest thing radiation oncology has to a guided missile.
On paper. The catch was always supply. Alpha-emitting isotopes like Lead-212 are produced in vanishingly small quantities, decay quickly, and have historically come from a handful of aging sources. You cannot run a global clinical program - let alone treat patients at scale - on an isotope you can barely get.
So the field had a strange shape. Brilliant targeting molecules waited on a shelf because there was nothing reliable to attach them to. The bottleneck was not biology. It was logistics, half-life, and the simple absence of enough material.
AdvanCell looked at that bottleneck and made an unfashionable decision. Instead of waiting for someone else to solve supply, it would build the supply itself - generator technology that turns Thorium-228 into a scalable, GMP stream of Lead-212.
AdvanCell was founded in 2019 by Andrew Adamovich. His first degree was in English and History from UC Berkeley, which is a useful reminder that the people who reshape an industry are not always the ones the industry expected. He bet that owning the isotope was not a side quest - it was the company.
It is the kind of bet that looks obvious only in hindsight. Building isotope production is capital-heavy, regulation-heavy, and patience-heavy. The fashionable move would have been to license the molecule and outsource the hard chemistry. AdvanCell did the reverse: it planted itself at the most stubborn point in the value chain and refused to move.
By 2025 that thesis had attracted serious money. An oversubscribed US$112M Series C - reported at roughly A$178M - was co-led by SV Health Investors, Sanofi Ventures, Abingworth and SymBiosis, with Eli Lilly, Morningside, Tenmile and Brandon Capital alongside. When Sanofi and Lilly both show up, the question stops being whether the science is interesting and starts being how fast it can scale.
Andrew Adamovich now serves as Managing Director, Australia. Philina Lee, PhD took the CEO seat to lead the US push - new HQ near Boston, same isotope.
Andrew Adamovich starts AdvanCell with a contrarian thesis: own the Lead-212 supply, then build the medicine.
The lead 212Pb-PSMA candidate begins evaluation in metastatic castration-resistant prostate cancer at Brisbane hospital sites.
Oversubscribed financing co-led by SV Health, Sanofi Ventures, Abingworth and SymBiosis - with Eli Lilly on board.
Promising Phase 1b clinical results for ADVC001 presented to the global oncology community.
Philina Lee, PhD appointed Chief Executive Officer to drive global growth from a new Boston-area HQ.
TheraPb Phase 2 expansion trial begins; first high-activity Thorium-228 delivery confirms a rare supply capability.
The engine room is the alpha isotope generator: proprietary technology that produces a scalable, GMP supply of Lead-212 from Thorium-228. Think of it as a tap. Open it, and you can finally feed a pipeline instead of a single experiment.
The first thing through the tap is ADVC001, a Lead-212-based PSMA-targeted alpha therapy for prostate cancer. PSMA is a marker that studs the surface of prostate cancer cells. Attach a homing molecule to Lead-212, point it at PSMA, and the alpha payload rides straight to the tumor. The radiation does its damage over a few cell-widths and then, by physics, stops.
212Pb-PSMA lead asset. Phase 1b data at ESMO 2025; now in the TheraPb Phase 2 expansion trial.
Targeted alpha therapy candidate advancing toward the clinic for melanoma.
Earlier-stage program aimed at several solid tumors with significant unmet need.
The supply engine - GMP Lead-212 that can power AdvanCell's own drugs and, potentially, partners' programs.
Each candidate is a different homing molecule bolted to the same warhead. Change the address; keep the explosive.
Skeptics are right to ask for evidence. Here is what is public. The Series C was oversubscribed - investors wanted in more than AdvanCell was selling. The Phase 1b readout at ESMO 2025 was encouraging enough to justify a Phase 2 expansion. And the Thorium-228 delivery is not a press-release flourish; receiving and handling high-activity Th-228 is a capability only a short list of organizations possess.
Partnerships round out the picture. A collaboration and exclusive licensing deal with 48Hour Discovery targets a peptide-based Lead-212 therapeutic for a gastrointestinal cancer. Research ties run through the Prostate Cancer Foundation, Peter MacCallum Cancer Centre, the Translational Research Institute and the University of Adelaide. A Thorium-228 supply relationship with Thor Medical keeps the tap flowing.
A biotech is only as credible as the institutions willing to attach their names to it. AdvanCell's list is getting long.
The mission AdvanCell repeats is plain: change the course of cancer treatment. The mechanism behind that sentence is the appealing part. Alpha therapy promises to be brutal to tumors and gentle to everything else - the opposite of the blunt-instrument reputation radiation has carried for a century.
For patients with metastatic castration-resistant prostate cancer, where options run thin, a therapy that finds the cancer by its molecular signature and spares healthy tissue is not a marketing line. It is the difference between treatment that wears you down and treatment that leaves room to live.
Return to Brisbane, to that shipment of Thorium-228 arriving at the dock. A few years ago, a delivery like that would have been the end of a story - a rare, precious thing to be hoarded and rationed. At AdvanCell it is the beginning of one. The thorium becomes lead, the lead becomes medicine, and the medicine goes looking for cancer.
The whole field once stalled at supply. AdvanCell's wager was that whoever turned a trickle into a tap would not just make a drug - they would make a platform. Each new targeting molecule becomes a new program. Each program shares the same engine. Prostate today; melanoma, ovarian, breast and lung in the queue behind it.
There is irony in it, the kind Wilde would have enjoyed: the breakthrough was not a molecule or a particle. It was a decision to do the boring, capital-heavy, regulation-soaked work of manufacturing - the part everyone else wanted to skip. AdvanCell skipped nothing. It started there.
The thorium arrives. The tap opens. Somewhere, a tumor gets a delivery it will not survive. That is the course AdvanCell set out to change - one short-range particle at a time.
Searching for an AdvanCell product demo or YouTube interview? The company keeps a low video profile - check the LinkedIn page and newsroom above for the latest talks and clinical updates.